Sinovac's COVID-19 vaccine over 50% effective in Brazil tests, reports newspaper Folha
SAO PAULO (Reuters) - Sinovac Biotech's vaccine against COVID-19 is over 50% effective in late-stage studies, Folha de S. Paulo newspaper reported on Wednesday, adding that the Chinese company had asked the Brazilian institute to conduct tests perform to wait 15 days before publishing full results.
The Butantane Institute, which is running the process in Brazil, and the Sao Paulo government, which oversees the institute, declined to comment, saying it would provide more details in a 4pm press conference. Local time.
If researchers withhold the full results, it will be the third time the institute has done so after initially promising to provide efficacy data in early December. Any delay would be a backlash to Beijing's efforts to catch up with Western drug manufacturers in the fight against the pandemic.
Scroll to continue with the content
Yeni CLIO Modelleri ile Tanışın
Yeni Renault Clio ile tanışmak, göz alıcı tasarımını ve yeni teknolojik özelliklerini yakından incelemek için tıklayın!
Sinovac would be the second Chinese vaccine maker to deliver late-stage clinical trial results after the UAE announced this month that a vaccine from a Beijing-based unit of the China National Pharmaceutical Group (Sinopharm) has 86% efficacy.
Competitive products developed by AstraZeneca Plc, Pfizer and Moderna achieved positive results with more detail in November.
(Reporting by Gabriel Araujo and Pedro Fonseca, Writing by Gabriel Stargardter, Editing by Brad Haynes and Sonya Hepinstall)
You should check here to buy the best price guaranteed products.
2 dead after man jumps from NY building and hits another
Prince Andrew formally served sex assault lawsuit in US
‘A heavy heart.’ Third employee from same Ky. elementary school dies of COVID-19.
'People have many different routes:' Climate scientist calls for action
September snow falls in the Northwest
The Price Is Right - An Extra Nice One Wrong Price